Viking Therapeutics will report its Q3 2026 results on October 28, with a key focus on its newly launched oral VK2735 Phase 3 obesity treatment program. The company’s shares have dropped over 41% in the past month, pressured by a recent stock offering and concerns about rising R&D costs. Investors will watch closely for details on dosing, trial progress, and maintenance data that could show competitive advantages over existing obesity drugs. Management’s outlook on spending and trial timelines will be crucial for the stock’s valuation going forward.
Viking Therapeutics' upcoming Q3 2026 results and obesity drug focus provide context for health sector activity. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 25, 2026 19:21 WIB: of 150 priced stocks, 44 rose and 105 fell. Notable moves include CTXR at USD 0.40 (+8.79%), LQDA at USD 42.65 (+7.46%), and OSCR at USD 30.99 (-6.99%).
Chery unveiled its Globalisation 3.0 strategy at the 2026 International User Summit, aiming to transform from a traditional automaker into a high-tech integrated ecosystem by 2035. The strategy emphasizes AI adoption, green technologies, and local ma...
Mastercard will report its third-quarter earnings on October 29, with shares near all-time highs after a recent 11.54% rise. Investors are focused on three key metrics: value-added services growth, which was 20% in Q2 but faces tougher comparisons; c...
Eli Lilly will report its Q3 2026 earnings on October 29, following five consecutive beats on earnings per share (EPS). The company showed strong revenue growth last quarter, driven by blockbuster drugs Mounjaro and Zepbound, with management raising ...
Intel will report its third-quarter results on October 29, with profit margins expected to be the key focus after shares dropped 13.24% since July. The last quarter showed record revenue and strong growth in data center and AI segments, but a large n...
Merck will report its Q3 2026 results on October 29, with investors focused on whether new drug launches like LIPFENDRA, QLEX, and WINREVAIR can compensate for the expected loss of patent exclusivity for Keytruda in 2028. Last quarter, revenue grew 5...
